0001213900-23-041168.txt : 20230518
0001213900-23-041168.hdr.sgml : 20230518
20230518160511
ACCESSION NUMBER: 0001213900-23-041168
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230517
FILED AS OF DATE: 20230518
DATE AS OF CHANGE: 20230518
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Collins James J.
CENTRAL INDEX KEY: 0001779269
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40410
FILM NUMBER: 23936044
MAIL ADDRESS:
STREET 1: C/O FULCRUM THERAPEUTICS, INC.
STREET 2: 26 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Orion Biotech Opportunities Corp.
CENTRAL INDEX KEY: 0001847416
STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770]
IRS NUMBER: 000000000
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE VANDERBILT AVENUE, 26TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10017
BUSINESS PHONE: 212-303-7822
MAIL ADDRESS:
STREET 1: ONE VANDERBILT AVENUE, 26TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10017
4
1
ownership.xml
X0407
4
2023-05-17
1
0001847416
Orion Biotech Opportunities Corp.
ORIA
0001779269
Collins James J.
C/O ORION BIOTECH OPPORTUNITIES CORP.
ONE VANDERBILT AVENUE, 26TH FLOOR
NEW YORK
NY
10017
1
0
0
0
0
Class B ordinary shares
2023-05-17
4
D
0
40000
0.00
D
Class A ordinary shares
40000
0
D
On April 21, 2023, the Issuer announced that it will not consummate an initial business combination within the time period required. Pursuant to the Issuer's Amended and Restated Memorandum and Articles of Association (the "Articles") and in connection with the winding up of the Issuer, the Class B ordinary shares, par value $0.0001, held by the Reporting Person were surrendered for no compensation on May 17, 2023.
After giving effect to the Issuer's delisting and deregistration, the Reporting Person will no longer be subject to Section 16 reporting obligations.
/s/ Marcello Liguori, as attorney in fact for James Collins
2023-05-18